Market Data 
Markets
Replies to post #794 on Lexicon Pharmaceuticals Inc (LXRX)
03/28/25 7:46 AM
$LXRX announces an exclusive license agreement with $NVO for LX9851, a first-in-class, oral non-incretin development candidate for obesity and associated metabolic disorders.
— Bio Stocks™ (@BioStocks) March 28, 2025
Lexicon is eligible to receive upfront and near-term milestone payments of up to $75M
AI
